RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF

The present invention relates to an angiotensin II type 2 (AT2) receptor inhibitor, particularly to a compound having a structure of formula (I) or formula (I') such as a compound of Foimula C I, a pharmaceutical composition comprising the same, and its use as an AT2 receptor inhibitor and an agent for the prophylaxis or the treatment of an AT2 receptor-mediated disorders including pain, a cell proliferative disorder, aberrant nerve regeneration and the like, or a symptom associated therewith; or for regulating a reproductive function associated with AT2 receptors in a female patient. (see formula (I) (see formula I') (see formula CI).

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 23. Jan. Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

ZHAO YANPING [VerfasserIn]
WANG HONGJUN [VerfasserIn]
WANG YEMING [VerfasserIn]
LI XIANG [VerfasserIn]
JIANG YUANYUAN [VerfasserIn]
HUANG HUAI [VerfasserIn]
LI FAJIE [VerfasserIn]
ZHOU LIYING [VerfasserIn]
SHAO NING [VerfasserIn]
XIAO FENGPING [VerfasserIn]
ZOU ZHENGUANG [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
C07D: Heterocyclic compounds (macromolecular compounds c0 (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-01-23, Last update posted on www.tib.eu: 2024-04-22, Last updated: 2024-04-26

Patentnummer:

CA3094001

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA000824577